We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Illustration
Illustration

A new non-invasive test that uses saliva samples to accurately diagnose cases of prostate cancer was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The test developed by researchers at the Tehran University of Medical Sciences (Tehran, Iran) could allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.

A key challenge in cancer care is the diagnosis of prostate cancer, one of the most common cancers in men. Clinicians currently use invasive biopsies or tests for prostate-specific antigen levels to diagnose prostate cancer in the clinic. But prostate cancer can be hard to spot during the early stages and can be tricky to distinguish from benign prostatic hyperplasia (BPH), a benign enlargement of the prostate that can appear as men age.

In an effort to solve these issues, researchers have developed a new test for prostate cancer that uses saliva samples, which can be collected repeatedly and non-invasively. Their test distinguishes prostate cancer from BPH by testing saliva for eight different microRNAs that either support or suppress tumor growth. The researchers validated their test with saliva samples from 180 men between 45 and 50 years of age, 60 of whom had been diagnosed with prostate cancer using standard methods and 60 of whom had been diagnosed with BPH.

“The advantage of our study is the use of several microRNAs, which have been reported to be detectable in the blood much earlier than the progression of cancer, which makes for a better diagnosis, as well as the use of saliva as a non-invasive biological sample that causes little pain to patients,” said Dr. Jamal Amri of the Tehran University of Medical Sciences.

Related Links:
Tehran University of Medical Sciences 

Gold Supplier
Benchtop Auto Sample Transfer Processor
MGISTP-3000
New
Static Concentrator
BJP 20 Static Concentrator
New
Gold Supplier
Fully Automated ELISA Workstation
EUROLabWorkstation ELISA
New
Automated Immunoassay System
GSD Thunderbolt

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.